| Primary | Exercise Capacity, as Determined by Peak Oxygen Uptake | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ml/min/kg | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-0.07± 2.00
- OG001-0.12± 2.29
|
|
| |
| Secondary | Exercise Capacity, as Determined by Peak Oxygen Uptake | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ml/min/kg | | Change from Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Exercise Capacity as Determined by Walk Distance | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | meters | | Change from Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Composite Score Reflective of Clinical Status | Participants ranked sequentially with ranking stratified in one of three tiers based on:
- Death (lowest tier) The person with the shortest time from randomization to death is given the lowest rank within the tier.
- Hospitalizations due to cardiovascular or renal causes (middle tier) For patients alive, the ranking within this tier is based on time to hospitalization from randomization date. The person with the first cardiovascular or renal cause hospitalization will be given the lowest rank within the tier.
- Change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) from baseline (highest tier)
The use of three tiers within the ranking reflects the greater adverse impact of death or cardiovascular hospitalization on clinical status without an arbitrary assignment as to the relative value of these events in relation to changes in quality of life. Rank order: 1-189 (higher values are better) | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | units on a scale | | Measured at Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Exercise Capacity as Determined by Walk Distance | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | meters | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Cardiopulmonary Exercise Test (CPET) Duration | To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | minutes | | Change from Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Cardiopulmonary Exercise Test (CPET) Duration | To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | minutes | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Ventilatory Anaerobic Threshold | To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ml/min/kg | | Change from Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Ventilatory Anaerobic Threshold | To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ml/min/kg | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Minnesota Living With Heart Failure Questionnaire (MLWHFQ) | The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment. Total score: 0 - 105 Physical subscore: 0 - 40 Emotional subscore: 0 - 25 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | units on a scale | | Change from Baseline to Week 12 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Secondary | Minnesota Living With Heart Failure Questionnaire | The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment. | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | units on a scale | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular Mass | A decrease in LV Mass is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | gm | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular Mass Index | A decrease in Left Ventricular Mass Index is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | gm/m^2 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular End Diastolic Volume | An increase in Left Ventricular End Diastolic Volume is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular End Diastolic Volume Index | An increase in Left Ventricular End Diastolic Volume Index is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mL/m^2 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular End Systolic Volume Index | An increase in Left Ventricular End Systolic Volume Index is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mL/m^2 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Left Ventricular Ejection Fraction (LVEF) | An increase in LVEF is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | percentage of volume | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Echocardiogram Left Ventricular Mass | A decrease in Left Ventricular Mass is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | gm | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Medial Diastolic Elastance | A decrease in Medial Diastolic Elastance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | (m/sec)/cc | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Lateral Diastolic Elastance | A decrease in Lateral Diastolic Elastance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | (m/sec)/cc | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Medial Left Ventricular Relaxation | An increase in Left Ventricular relaxation is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | m/sec | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Lateral Left Ventricular Relaxation | An increase in Left Ventricular relaxation is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | m/sec | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Medial Filling Pressure | A decrease in medial filling pressure is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | m/sec | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Lateral Filling Pressure | A decrease in lateral filling pressure is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | m/sec | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | ECHO Effective Arterial Elastance | A decrease in Effective Arterial Elastance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | Farads-1 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | ECHO Systemic Vascular Resistance | A decrease in Systemic Vascular Resistance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | Woods units | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Effective Arterial Elastance | A decrease in Effective Arterial Elastance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | Farads-1 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Systemic Vascular Resistance | A decrease in Systemic Vascular Resistance is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | Woods units | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Aortic Thickness | A decrease in Aortic Thickness is considered an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mm | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | MRI Aortic Distensibility | An increase in Aortic Distensibility is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | cm^2*dyne-1 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | ECHO Pulmonary Artery Systolic Pressure | A decrease in Pulmonary Artery Systolic Pressure is considered to be an improvement | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mmHg | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Best Available Creatinine | Best available=local lab results only when core lab results not available | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mg/dL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Best Available Glomerular Filtration Rate (GFR) | Best available=local lab results when core lab results not available | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mL/min/1.73m^2 | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Cystatin C | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mg/L | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Uric Acid | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mg/dL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP) | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | pg/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Aldosterone | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | pg/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | High Sensitivity Troponin I | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | pg/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Procollagen III N-terminal Peptide | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ug/L | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Endothelin-1 | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | pg/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | High Sensitivity C-Reactive Protein | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mg/L | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Collagen Type I (CITP) | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ug/L | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Cyclic Guanosine Monophosphate (cGMP) | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | pmol/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Galectin 3 | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | ng/mL | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |
| Other Pre-specified | Furosemide-Equivalent Dose | | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | Posted | | Mean | Standard Deviation | mg | | Change from Baseline to Week 24 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks | | OG001 | Sildenafil | sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks |
| |